Oncology Update, ASCO 2022 Top 3 Trending Interviews
Roy S. Herbst, MD, PhD
Yale Cancer Center and Smilow Cancer Hospital
|
ASCO 2022: Phase II S1800A Trial
Overall survival from a randomized study for advanced NSCLC previously treated with immunotherapy
|
Summanta (Monty) Pal, MD
City of Hope
|
ASCO 2022: Results from Cohorts 3, 4, 5 of the COSMIC-021 Study
Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC)
|
Karim Chamie, MD UCLA Health
|
ASCO 2022: Phase 2/3 QUILT-3.032 Trial
Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary NMIBC
|